General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0UMBUN
ADC Name
aCSPG4 (scFv)-SNAP-AURIF
Synonyms
aCSPG4 (scFv)-SNAP-AURIF
   Click to Show/Hide
Organization
University of Cape Town.; Seattle Children's Research Institute.; Cedars-Sinai Medical.; University of Johannesburg.; University of Witwatersrand.; TUBE Pharmaceuticals.
Drug Status
Investigative
Antibody Name
aCSPG4 (scFv)-SNAP
 Antibody Info 
Antigen Name
Chondroitin sulfate proteoglycan 4 (CSPG4)
 Antigen Info 
Payload Name
Monomethyl auristatin F
 Payload Info 
Therapeutic Target
Microtubule (MT)
 Target Info 
Linker Name
Undisclosed
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (lC50) 
173.3
nM
CVCL_0332
Invasive breast carcinoma of no special type
Half Maximal inhibitory Concentration (lC50) 
190.3
nM
CVCL_0419
Breast adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
1660
nM
CVCL_0526
Cutaneous melanoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
173.3 nM
Method Description
Cells (5 × 103) were seeded in a 96-well plate (in either RPMI-1640 (Gibco #10566) or DMEM medium (Gibco #61870), supplemented with 10% (v/v) heat-inactivated FBS and 1% (v/v) 100 U/mL penicillin-streptomycin) and allowed to adhere overnight under standard tissue culture conditions (37 °C, 5% CO2 and 95% humidity). The next day, they were treated with threefold serially diluted concentrations of MMAF (unmodified), BG-linker-AURIF, alphaCSPG4 (scFv)-SNAP (unconjugated) or alphaCSPG4 (scFv)-SNAP-AURIF and incubated for 72 h in a 5% CO2 incubator with 95% humidity at 37 °C. Untreated cells served as negative controls (100% cell viability), while Zeocin-treated (100 ug/mL) cells were used as positive controls (0% cell viability). The Cell Proliferation Kit II (XTT) (product number: 11465015001, Roche, Switzerland) was used (according to the manufacturer's protocol) to assess cytotoxicity. In this assay, cleavage of the tetrazolium salt XTT occurs in the presence of metabolically active cells and results in the formation of orange formazan crystals, which absorb light at 450 nm. Thus, at 68 h post-treatment, cells were treated with the XTT reagent and at 72 h, absorbance readings (at 450 nm as the measurement filter and 650 nm as the reference filter) were taken using a spectrophotometer (iMarkTM Microplate Absorbance Reader, Bio-Rad, USA). All experiments were carried out in triplicate (n = 3), with 3 technical repeats. The absorbance values were normalized with respect to the untreated and Zeocin controls, and the results were presented as a percentage of cell viability. The concentration required to achieve a 50% reduction in cell viability (IC50 value) was calculated using GraphPad Prism v5 software.

   Click to Show/Hide
In Vitro Model Invasive breast carcinoma of no special type Hs578T cells CVCL_0332
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
190.3 nM
Method Description
Cells (5 × 103) were seeded in a 96-well plate (in either RPMI-1640 (Gibco #10566) or DMEM medium (Gibco #61870), supplemented with 10% (v/v) heat-inactivated FBS and 1% (v/v) 100 U/mL penicillin-streptomycin) and allowed to adhere overnight under standard tissue culture conditions (37 °C, 5% CO2 and 95% humidity). The next day, they were treated with threefold serially diluted concentrations of MMAF (unmodified), BG-linker-AURIF, alphaCSPG4 (scFv)-SNAP (unconjugated) or alphaCSPG4 (scFv)-SNAP-AURIF and incubated for 72 h in a 5% CO2 incubator with 95% humidity at 37 °C. Untreated cells served as negative controls (100% cell viability), while Zeocin-treated (100 ug/mL) cells were used as positive controls (0% cell viability). The Cell Proliferation Kit II (XTT) (product number: 11465015001, Roche, Switzerland) was used (according to the manufacturer's protocol) to assess cytotoxicity. In this assay, cleavage of the tetrazolium salt XTT occurs in the presence of metabolically active cells and results in the formation of orange formazan crystals, which absorb light at 450 nm. Thus, at 68 h post-treatment, cells were treated with the XTT reagent and at 72 h, absorbance readings (at 450 nm as the measurement filter and 650 nm as the reference filter) were taken using a spectrophotometer (iMarkTM Microplate Absorbance Reader, Bio-Rad, USA). All experiments were carried out in triplicate (n = 3), with 3 technical repeats. The absorbance values were normalized with respect to the untreated and Zeocin controls, and the results were presented as a percentage of cell viability. The concentration required to achieve a 50% reduction in cell viability (IC50 value) was calculated using GraphPad Prism v5 software.

   Click to Show/Hide
In Vitro Model Breast adenocarcinoma MDA-MB-468 cells CVCL_0419
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
1660 nM
Method Description
Cells (5 × 103) were seeded in a 96-well plate (in either RPMI-1640 (Gibco #10566) or DMEM medium (Gibco #61870), supplemented with 10% (v/v) heat-inactivated FBS and 1% (v/v) 100 U/mL penicillin-streptomycin) and allowed to adhere overnight under standard tissue culture conditions (37 °C, 5% CO2 and 95% humidity). The next day, they were treated with threefold serially diluted concentrations of MMAF (unmodified), BG-linker-AURIF, alphaCSPG4 (scFv)-SNAP (unconjugated) or alphaCSPG4 (scFv)-SNAP-AURIF and incubated for 72 h in a 5% CO2 incubator with 95% humidity at 37 °C. Untreated cells served as negative controls (100% cell viability), while Zeocin-treated (100 ug/mL) cells were used as positive controls (0% cell viability). The Cell Proliferation Kit II (XTT) (product number: 11465015001, Roche, Switzerland) was used (according to the manufacturer's protocol) to assess cytotoxicity. In this assay, cleavage of the tetrazolium salt XTT occurs in the presence of metabolically active cells and results in the formation of orange formazan crystals, which absorb light at 450 nm. Thus, at 68 h post-treatment, cells were treated with the XTT reagent and at 72 h, absorbance readings (at 450 nm as the measurement filter and 650 nm as the reference filter) were taken using a spectrophotometer (iMarkTM Microplate Absorbance Reader, Bio-Rad, USA). All experiments were carried out in triplicate (n = 3), with 3 technical repeats. The absorbance values were normalized with respect to the untreated and Zeocin controls, and the results were presented as a percentage of cell viability. The concentration required to achieve a 50% reduction in cell viability (IC50 value) was calculated using GraphPad Prism v5 software.

   Click to Show/Hide
In Vitro Model Cutaneous melanoma SK-MEL-28 cells CVCL_0526
References
Ref 1 CSPG4 as a target for the specific killing of triple-negative breast cancer cells by a recombinant SNAP-tag-based antibody-auristatin F drug conjugate